Business Context and Reporting Period
Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2020
Business Overview: Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease (PD) and related disorders. The company utilizes small molecule, oral protein kinase inhibitors targeting the c-Abl enzyme. Its lead asset, IkT-148009, is in Phase 1 clinical trials for PD and gastrointestinal complications associated with PD. The company also has an oncology program, IkT-001Pro (a prodrug of Imatinib for Chronic Myelogenous Leukemia), which is in preclinical development. The company completed its Initial Public Offering (IPO) in December 2020.
Key Financial Metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Grant Revenue | $698,468 | $1,122,740 |
| Total Expenses | $3,516,960 | $6,820,888 |
| Net Loss | $(2,847,894) | $(5,722,983) |
| Cash and Cash Equivalents (Year End) | $13,953,513 | $18,457 |
| Working Capital | $10,060,817 | $(4,217,514) |
| Accumulated Deficit | $(15,031,624) | $(12,183,730) |
| Net Cash Used in Operating Activities | $(1,129,355) | $(338,290) |
| Net Cash Provided by Financing Activities | $15,064,411 | $(22,810) |
Note: The company has no product sales revenue. Revenue is derived entirely from grants and contracts.
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue decreased by 37.8% ($424,272) compared to 2019, driven by a shift in focus toward advancing Phase I clinical trials which did not generate grant revenue.
- Expense Reduction: Total operating expenses decreased by approximately 48%. Research and Development (R&D) expenses dropped 65.0% to $893,802, and Selling, General, and Administrative (SG&A) expenses dropped 38.5% to $2,623,158. The SG&A decrease was largely due to the absence of a $1.59 million one-time charge for deferred IPO costs expensed in 2019.
- Net Loss Improvement: Net loss decreased by 50.2% to $2.85 million, primarily due to the reduction in operating expenses.
- Liquidity Transformation: Cash balances increased from $18,457 in 2019 to $13.95 million in 2020. This was driven by net proceeds of approximately $14.6 million from the December 2020 IPO and $272,800 from a note payable to the CEO.
- Capital Structure: The company completed a reverse stock split (1-for-1.14396) in August 2020 and converted a significant portion of debt (Flagship Consulting Note) into common stock upon the IPO closing.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: The independent registered public accounting firm has included an explanatory paragraph in its audit report stating that the company's recurring losses, working capital deficit (prior to IPO), and accumulated deficit raise substantial doubt about its ability to continue as a going concern. Management plans to alleviate this through additional equity raises and cost reductions.
- Clinical Milestones:
- IkT-148009 (PD): First dosing of patients commenced in February 2021. The company anticipates initiating a Phase 1b study in the next 12 months, subject to financing.
- IkT-001Pro (CML): The company plans to submit an Investigational New Drug (IND) application in the second quarter of 2021. Clinical development could potentially be completed in 2022 if FDA agreements and funding are secured.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future. It will require substantial additional funding to complete clinical trials and commercialize products. Failure to raise capital could force the company to delay, reduce, or discontinue development programs.
- Key Risks:
- Drug Development Risk: High uncertainty in clinical trials; preclinical success does not guarantee human efficacy.
- Regulatory Risk: Reliance on FDA approval pathways (including 505(b)(2) for IkT-001Pro) which are unpredictable.
- Intellectual Property: Dependence on patents and licenses (e.g., Emory University, Sphaera Pharma) which may be challenged or expire.
- Third-Party Reliance: Reliance on contract research organizations (CROs) and manufacturers, including facilities in China, for clinical trials and production.
- COVID-19 Impact: Potential delays in clinical trial enrollment and operations due to the pandemic.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.95 million cash balance to fund operations through the next 12-18 months, considering the "substantial doubt" regarding going concern status.
- Grant Dependency: Assess the sustainability of revenue streams, noting that over 90% of historical revenue comes from government and foundation grants, which are not guaranteed.
- Clinical Trial Progress: Monitor the status of the Phase 1 trial for IkT-148009 (dosing began Feb 2021) and the planned IND submission for IkT-001Pro (Q2 2021).
- Dilution Risk: Review the impact of future equity financings required to fund operations, given the company's lack of product revenue and significant accumulated deficit.
- Related Party Transactions: Review the terms of the CEO Note ($248,911 outstanding) and the conversion of the CFO's note into equity, as well as the employment agreements with significant severance provisions.
- Intellectual Property Ownership: Confirm the status of joint ownership with Sphaera Pharma regarding the prodrug technology and the terms of the Emory University license.